

Food and Drug Administration
Rockville MD 20857

NDA 20-221/S-002

U.S. Bioscience, Inc.
One Tower Bridge
100 Front Street
West Conshohocken, PA 19428

MAR 15 1996

Attention: Barbara Scheffler
Senior Vice President for Clinical Operations
and Regulatory Affairs

Dear Ms. Scheffler:

We acknowledge your February 8, 1996 supplemental new drug application received on February 9, 1996 under section 505(b) of the Federal Food, Drug, and Cosmetic Act for ETHYOL (amifostine) for Injection 500 mg.

We acknowledge receipt of your amendments dated February 20 and 26, and March 1, 1996.

The supplemental application provides for modification of Ethyol® indications, to include treatment of patients with non-small cell lung cancer.

We have completed the review of this supplemental application including the submitted draft labeling under the policies and procedures reflected in the Accelerated Approval Regulations 21 CFR 314.500 through 314.560. We have concluded that adequate information has been presented to demonstrate that the drug product is safe and effective for use as recommended in the draft labeling in the submission dated March 1, 1996. Accordingly, the supplemental application is approved effective on the date of this letter.

Products approved under the Accelerated Approval Regulations require further adequate and well-controlled studies to verify and describe clinical benefit. In this regard; we acknowledge your commitment in your letter dated February 8, 1996 to conduct a controlled clinical trial in patients with advanced non-small cell lung cancer to demonstrate that pretreatment with Ethyol® results in clinical benefit to the patient. We anticipate that your ongoing WR-53 study may fulfill this requirement, with statistical analytic plans determined in consultation with the Agency. We request that you submit the complete findings of this study as soon as possible for our review to satisfy the requirements of the Accelerated Approval Regulations.

The approval and subsequent marketing of this product and related activities are to be in accordance with the substance and procedures reflected in the Accelerated Approval Regulations referenced above.

The final printed labeling (FPL) must be identical to the draft labeling submitted on March 1, 1996.

Please submit fifteen copies of the FPL (package insert, immediate container and carton labeling) as soon as it is available, in no case more than 30 days after it is printed. Please individually mount ten of the copies on heavy weight paper or similar material. For administrative purposes this submission should be designated "FINAL PRINTED LABELING" for approved supplemental NDA 20-221/S-002. Approval of this labeling by FDA is not required before it is used.

Should additional information relating to the safety and effectiveness of the drug become available, revision of that labeling may be required.

In addition, please submit three copies of the introductory promotional material that you propose to use for this product. All proposed materials should be submitted in draft or mock-up form, not final print. Please send one copy to this Division and two copies of both the promotional material and the package insert directly to:

Food and Drug Administration
Division of Drug Marketing, Advertising and
Communications, HFD-240
5600 Fishers Lane
Rockville, Maryland 20857

Please submit one market package of the drug when it is available.

Validation of the regulatory methods has not been completed. At the present time, it is the policy of the Center not to withhold approval because the methods are being validated. Nevertheless, we expect your continued cooperation to resolve any deficiencies that may occur.

We remind you that you must comply with the requirements for an approved NDA set forth under 21 CFR 314.80 and 314.81.

If you have any questions, please contact Linda McCollum, Consumer Safety Officer, at (301) 594-5771.

Sincerely yours,

Robert DeLap 3/15/96

Robert DeLap, M.D., Ph.D.
Acting Director
Division of Oncology Drug Products
Office of Drug Evaluation I
Center for Drug Evaluation and Research